CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform.
CRISPR Therapeutics has raised $550.0M in total funding. The most recent round was Post-IPO Debt. The last funding was announced in March 2026.
CRISPR Therapeutics's investors include Franklin Templeton, Bill & Melinda Gates Foundation, New Enterprise Associates, Versant Ventures, Abingworth.
CRISPR Therapeutics is headquartered in Cambridge, United States.
CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform.
CRISPR Therapeutics is at the Post-IPO Debt stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"CRISPR Therapeutics — Funding & Investors." VCBacked, March 11, 2026, https://www.vcbacked.co/company/crispr-therapeutics. Accessed August 14, 2026.
VCBacked. (2026). CRISPR Therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/crispr-therapeutics
{{cite web |title=CRISPR Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/crispr-therapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated